More than 10 new drugs have been approved clinically from AbbVie, Converse, Johnson and Johnson, Bayer, etc.

Today, China's State Drug Administration Drug Review Center (CDE) announced that more than 10 new drugs have been approved for clinical trials.
these products include CGRP-controlled antagonists, new RSV fusion protein inhibitors, NOTCH inhibitors, TNF-alpha antagonists, CD47 antibodies, and others from AbbVie, Converse Bio, Johnson and Johnson, Fosun Pharma, Bayer, Roche, Sanofi, and others.
the products that have attracted much attention in the antho-section of this article.
1, AbbVie: atogepant tablets Target/Action Mechanism: CGRP-subject antagonist adaptation: Prevention of migraines This is a new oral calcitonin gene-related peptide (CGRP) peptide (CGRP) antagonist developed by Allergan, acquired by AbbVie, specifically developed for preventive treatment of migraines.
CGRP and its subjects are expressed in areas of the nervous system associated with migraine pathophysiology.
that CGRP levels increase during migraine attacks, and selective CGRP-subject antagonists can benefit migraine patients clinically.
In July, the product reached its primary endpoint in ADVANCE, a Phase 3 clinical trial to prevent migraines, and AbbVie plans to advance regulatory submissions in the U.S. and other countries based on the results of this Phase 3 clinical trial and previously aggressive Phase 2/3 clinical trial results.
2, United States medicine: Hemay007 tablets target / mechanism of action: immunomodulative drug adaptation: strong straight spina brysitis according to the United States medicine official website information, Hemay007 is immunomodulation drugs, a class 1 new drug, has been conducted in Australia clinical trials.
, the product has been approved clinically in China for development for rheumatoid arthritis.
Hemay007 is conducting a Phase 2 study of patients with active ulcerative colitis, according to the China Drug Clinical Trial Registration and Information Disclosure Platform.
3, Novo Nordisk: Semaglutide Injection Target/Mechanism of Action: GLP-1 Similar Adaptation: Intermittent lame Semaglutide (Somalutide) developed by Novo Nordisk to improve patients with type 2 diabetes combined with exosperial arterial disease is a long-acting human glutatrogin-like peptide-1 (GLP-1) similar developed by Novo Nordisk.
approved by the FDA in 2017, combined with diet and exercise, to help people with type 2 diabetes control blood sugar levels.
GLP-1 is a hormone secreted by the small intestine that promotes insulin and inhibits the secretion of glucosin after eating, thereby speeding up glucose metabolism.
GLP-1 similars can also play a role in slowing stomach emptying, inhibit appetite effect, so as to achieve the goal of weight loss.
4, Kangfang Bio: AK117 injection target/mechanism of action: CD47 antibody adaptation: advanced solid or lymphoma This is a target CD47 monoclonal antibody, has previously been approved by IND in the United States, and in May this year in Australia completed the first case of patients into the group and administration.
CD47 is an immunomodulation molecule that is overexpressed on tumor cells and plays an "accomplice" role in the development and development of cancer.
cells that express the CD47 protein are like sticking a "don't eat me" label on their body to avoid being swallowed by macrophages.
antibodies based on this development target CD47 can tear off the label and reactivate macrophages.
5, Janssen/Johnson: JNJ-53718678 Oral Suspension Target/Action Mechanism: RSV Fusion Protein Oral Inhibitor Adaptation: Treatment of Human Respiratory Syncytial Virus (RS) V) Caused respiratory diseases This is a new RSV fusion protein inhibitor developed by Johnson and Johnson's Janssen, which specific targets and binds fusion proteins to the surface of the virus, inhibits the fusion of RSV fusion proteins with host cell membranes, and prevents the virus from entering.
this can prevent the replication of RSV, reduce the viral load, and thus reduce the severity of the disease.
, JNJ-53718678 is in Phase 2 clinical phase, and this is the first time the product has been approved clinically in China.
6, Revance Therapeutics/Fosun Pharmaceuticals Industry: DaxibotulinumtoxinA Target/Mechanism of Action: RSV Fusion Protein Oral Inhibitor Adaptation: Prevention of Thromboulent Embolism DaxibotulinumtoxinA (RT00) 2) A new, next-generation, long-acting neuromodulant developed on Revance Therapeutics' proprietary technology platform, the drug's active ingredient is Daxibotulinumtoxin Type A Botuvirus, which has previously obtained positive top-line results in two key Phase 3 clinical trials.
studies have shown that RT002 can be used for beauty and treatment of symptoms including eyebrow lines, neck dystatic disorders and foot fascia.
In China, Fosun Pharma Pharmaceuticals, a controlling subsidiary of Fosun Pharmaceuticals, signed a licensing agreement with Revance Therapeutics in December 2018, and Fosun Pharmaceuticals will have exclusive rights to RT002 for exclusive use, import, sale and other commercialization (excluding manufacturing) in Chinese mainland, Hong Kong and Macau, authorizing applications including cosmetic and therapeutic adaptations.
just a few days ago, the product has been approved clinically in China, intended to be developed for medium to severe eyebrow tattoos.
7, Bayer: osocimab injection target/mechanism of action: FXIa inhibitor adaptation: Prevention of thrombosis Osocimab (a.k.a. BAY 1213790) is a Bayer coagulation factor XIa (FXIa) inhibitor.
recent studies have found that FXIa inhibitors can reduce the incidence of venous thrombosis without significantly affecting bleeding.
, it is considered to be of great potential value in the treatment of thrombosis, and FXIa inhibitors are considered to be a new type of anti-thrombosis drug.
has completed a Phase 2 clinical study to assess the safety and effectiveness of venous thromboembolism in patients with selective primary full knee replacement at different doses of BAY 1213790, according to the
Clinicaltrials.gov website.
8, Roche: lysioxid injection target/mechanism of action: CD20 antibody adaptation: treatment of moderate to severe common type of herpes (PV) adult patients lytoxic monoantigen is a monoclonal antibody, can be compared with CD20 antigen binding on the surface of B lymphocytes, mediated complement-dependent cytotoxic action (CDC) and antibody-dependent cell-mediated cytototoxic action (ADCC), mediated normal and malignant B cell dissolution in the body, in order to achieve anti-tumor treatment effect.
the drug has been approved in Europe and the United States since its launch in 1997, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and rheumatoid arthritis (RA).
2019, the product was approved by the European Commission for the treatment of adult herpes.
According to Roche's previous press release, this is the first biological therapy approved for treatment of a rare autoimmune disease, moderate to severe patients with common herpes, and the first major advance in the treatment of the disease in more than 60 years.
9, Dongsian Pharmaceuticals: HEC122505 MSOH tablet target/ mechanism of action: MAO-B reversible inhibitor adaptation: intended to be used in the treatment of Parkinson's disease with L-Doba This is a high-energy, highly selective type B monoamine oxidase (mono oxamineid Base, MAO-B) reversible inhibitor, clinically intended to treat left-handed dopamine disease.
by inhibiting MAO-B, it can reduce the degradation of dopamine and enhance the nerve function of dopamine.
10, Sanofi: Recombinant human coagulation factor VIII Fc-vascular haemophilia factor-XTEN fusion protein target/mechanism of action: clotting factor VIII alternative therapy adaptation: suitable for adults and children with haemophilia type A: bleeding On-demand treatment; conventional preventive treatment to reduce the frequency of bleeding; peri-surgical haemorrhage treatment This is an innovative coagulation factor VIII alternative therapy BIVV001 (rFVIIIFc-VWF-XTEN) developed by Sanofi in collaboration with Sobi.
its design connects FVIII to a VWF fragment, the resulting complex does not combine with the natural VWF in the blood, thus breaking the half-life limit set by VWF.
aims to allow haemophilia A patients to achieve near-normal levels of FVIII factor activity for most of the week after receiving an injection.
recently, the product obtained positive results in a Phase 1/2a clinical trial, with BIVV001 increasing half-life by 3-4 times compared to traditional clotting factor VIII (FVIII) alternative therapies.
attention to the "Drug Mingkang" WeChat public number.